环胺减轻肺动脉高血压的发展:对病理生理学的刺信号参与的影响
Makito Sakurai1, Susumu Hosokawa1,2, Yohei Yamaguchi1
1Department of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.
概括
用环胺抑制刺信号传递有效地通过减少血管重塑来治疗肺动脉高血压 (PAH). 这种新的方法显示出对管理这种严重的肺部疾病的希望.
科学领域:
- 肺高血压研究 肺高血压研究
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺动脉高血压 (PAH) 是一种严重的肺病,治疗选择有限.
- 目前的组合疗法可以改善生存率,但不能完全解决PAH管理的未满足需求.
- 刺 (HH) 信号通路与疾病的发生有关.
研究的目的:
- 调查 (HH) 信号抑制剂环胺,作为PAH的新疗法.
- 在PAH小鼠模型中评估环胺对肺血管改造和相关生理变化的影响.
主要方法:
- 通过将C57BL/6J小鼠暴露在缺氧中,建立了肺高血压的小鼠模型.
- 在暴露于缺氧后,小鼠接受了循环胺或载体治疗.
- 分析了生理参数 (右心室缩压,RV高),血管重塑 (动脉肌化) 和细胞/分子途径 (单细胞RNA测序,hPASMCs的RNA测序).
主要成果:
- 在缺氧小鼠中,环胺显著降低了右心室缩压和高.
- 用环胺治疗显著降低了完全肌肉化的小肺动脉的百分比,这表明血管重塑的抑制.
- 在体外研究表明,环胺抑制了人类肺动脉平滑肌细胞 (HPASMCs) 的缺氧诱导的增殖.
- 单细胞RNA测序揭示了血管光滑肌收缩和cGMP-PKG信号通路的抑制.
- 对hPASMCs的RNA测序显示了细胞外矩阵调节通路的恢复.
结论:
- 黑 (HH) 信号抑制与环胺证明了肺动脉高血压 (PAH) 的治疗潜力.
- 环胺有效地抑制了肺血管重塑,这是PAH的关键驱动因素.
- 这项研究支持HH信号抑制作为管理PAH的有希望的策略.
相关概念视频
02:33Hedgehog Signaling Pathway
7.3K
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.3K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
92
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
92
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
87
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
87
01:30Pulmonary Hypertension: Classification and Pathogenesis
106
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
106
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
101
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
101
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
88
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
88